Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

BACKGROUND: The gold standard endpoint in clinical trials of chemotherapy and radiotherapy for lung cancer is overall survival. Although reliable and simple to measure, this endpoint takes years to observe. Surrogate endpoints that would enable earlier assessments of treatment effects would be usefu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauguen, Audrey, Pignon, Jean-Pierre, Burdett, Sarah, Domerg, Caroline, Fisher, David, Paulus, Rebecca, Mandrekar, Samithra J, Belani, Chandra P, Shepherd, Frances A, Eisen, Tim, Pang, Herbert, Collette, Laurence, Sause, William T, Dahlberg, Suzanne E, Crawford, Jeffrey, O'Brien, Mary, Schild, Steven E, Parmar, Mahesh, Tierney, Jayne F, Pechoux, Cécile Le, Michiels, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2013
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732017/
https://www.ncbi.nlm.nih.gov/pubmed/23680111
http://dx.doi.org/10.1016/S1470-2045(13)70158-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3732017/
https://www.ncbi.nlm.nih.gov/pubmed/23680111
http://dx.doi.org/10.1016/S1470-2045(13)70158-X

Ejemplares similares